Executive Briefing
• The objective of this study was to review current evidence for the comparative costeffectiveness of pharmacological treatments for attention deficit hyperactivity disorder (ADHD) and assess the budget impact of alternative policies for reimbursing pharmacotherapies in the treatment of ADHD
• We did not find any published economic evaluations that were eligible for inclusion in our review of the comparative cost-effectiveness of adult ADHD medications; however, we were able to conduct a post-hoc literature review to assess the impact of adult ADHD on work performance and criminality
• Findings from this post-hoc review were generally supportive of an association between adult ADHD and increased unemployment and poorer work performance and that pharmacological treatment of ADHD symptoms is associated with improved work performance and reduced likelihood of criminal behaviour
• These results have limited applicability in the Canadian context and should be interpreted with caution
• Based on data from OPDP from 2000-2014, spending on adult ADHD medications was $14.6 million in 2014 and is projected to increase to $23.2 million by 2017
• Listing atomoxetine as Limited Use in addition to a general benefit listing for extended release methylphenidate and a limited use listing for brand name only long-acting stimulants with enforced step therapy is expected to result in the greatest reduction (-13%) in overall expenditure for adult ADHD medications by 2017.
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Research Questions
RQ1. What is the current evidence for the comparative cost-effectiveness of pharmacological treatments for attention deficit hyperactivity disorder (ADHD)?
RQ2. What is the budget impact of alternative policies for reimbursing pharmacotherapies in the treatment of ADHD?
Systematic Review of Published Economic Evaluations
A total of 93 unique citations relating to the cost-effectiveness of treatments for adults with ADHD were identified from our initial searches and were screened for inclusion in this review. All 93 of the records that were reviewed for inclusion were deemed irrelevant to our research question and were eliminated from our review. Given the lack of evidence regarding the costeffectiveness of treatments for ADHD among adults, we conducted a post-hoc literature review to outline the societal impact of adult ADHD on employment and criminality.
Using a combination of hand-searching and database searching with keywords, we were able to identify some relevant literature regarding the link between adult ADHD and employment/criminality. Findings from these studies were supportive of an association between adult ADHD and increased unemployment and poorer work performance. We also identified a few studies providing evidence that receiving treatment for ADHD helps to improve work performance and reduce criminal behaviour. Again, findings from these studies were generally supportive of the notion that pharmacological treatment of ADHD symptoms is associated with improved work performance and reduced likelihood of criminal behaviour. However, in both instances, the studies we reviewed were generally of poor quality and had several limitations including, small numbers of participants and poor generalizability. There was also little mention of the economic implications of adult ADHD from a broader societal perspective. None of the studies that we reviewed were conducted in the Canadian context, further limiting the applicability of this evidence to our study question.
Based on the findings from both our systematic review and our post-hoc literature review, we have determined that little is known about the economic impact of adult ADHD. There is a clear need for more research in this area to address questions of cost-effectiveness and economic burden on the health care system.
For a detailed report of the review of economic literature relative to this drug class, please refer to Appendix A -Systematic Review of Economic Evidence.
Budget Impact Analysis
Among adults (≥18 years) spending on ADHD medications has risen from about $736,000 in 2000 to over $14.5 million in 2014. Similarly, among children expenditure has increased $1.5 million to $10.7 million over the last 15 years. Without changes to current reimbursement for ADHD medications, expenditure is expected to rise to $12.1 million in 2017 for children and $23.2 million for adults.
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Listing atomoxetine as limited use in addition to a general benefit listing for extended release methylphenidate and a limited use listing for brand name only long-acting stimulants with enforced step therapy (strategy 3b) would generate the greatest reduction (-13%) in overall expenditure for adult ADHD medications by the end of 2017. Strategy 2b (LU listing for atomoxetine and long-acting stimulants with enforced step therapy) and strategy 3a (GB for extended release methylphenidate and LU listing/step therapy for brand name only longacting stimulants) would each lead to an 8% decrease in overall adult ADHD medication expenditure. Strategies 1b, 2a and 4 would also result in reductions in overall expenditure for adult ADHD medication from 3-5%.
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Appendices Appendix A -Systematic Review of Economic Evidence Research Question
What is the current evidence for the comparative cost-effectiveness of pharmacological treatments for attention deficit hyperactivity disorder (ADHD)?
Review of Published Literature Search Strategy and Search Findings
Search Strategy 
Search Findings
A total of 97 citations relating to the cost-effectiveness of treatments for adults with ADHD were identified from the initial searches, all of which were found through database searching with no additional records identified from grey literature sources. Following the removal of duplicate records, 93 unique citations were retrieved for screening.
One reviewer (KT) reviewed the titles and abstracts of studies identified by the search strategy in order to identify potential articles for critical appraisal, a second reviewer (ML) was available where confirmatory screening was required. We did not identify any articles of potential relevance to our research question from the 93 citations that were screened; therefore, 0 articles were selected for full-text review. Refer to Figure 1 in Appendix A2: Results of Search for more details about the results from our search. A list of excluded studies is included in Appendix A3: List of Excluded Studies.
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Ontario Drug Policy Research Network adults, we conducted a post-hoc literature review to outline the societal impact of adult ADHD on employment and criminality. To do this, we developed a non-exhaustive search strategy to identify potentially relevant literature regarding the link between ADHD and employment/criminality. We also searched reference lists of relevant articles to identify any additional literature. Findings from this post-hoc literature review are reported below.
Findings from post-hoc literature review
Although ADHD is better recognized in childhood, there is increasing evidence that some symptoms remain or present during adulthood and can have an impact on societal factors, such as work performance and retention, and criminality. 1, 2 The effectiveness of ADHD treatment on improving societal outcomes is not well understood. The bulk of the studies contributing to the literature base is often methodologically flawed and includes small numbers of adults with ADHD. What follows is a brief review of some of the observational evidence suggesting a link between adult ADHD and employment and criminality. We also review a few studies providing evidence that receiving treatment for ADHD helps to improve work performance and reduce criminal behaviour. By reviewing this evidence, we hope to better understand the potential economic implications of adult ADHD and its treatment from a broader, societal perspective.
There are several studies that have identified an association between adult ADHD and increased unemployment and poorer work performance. A recent study from Germany found that 4.7% (n=78) of 1655 participants met the criteria for adult ADHD based on a self-report screening instrument. Among the 78 participants, authors note a positive and statistically significant association between adult's diagnosed with ADHD and unemployment (odds ratio: 2.1, 95% confidence interval: 1.1-4.0). 3 Similarly, results from the World Health Organization's World Mental Health Survey Initiative found that an average of 3.5% of workers met the DSM-IV criteria for adult ADHD, and that ADHD was significantly associated with 22.1 annual days of lost role performance compared to participants without ADHD. 4 A third survey study conducted in the United States reports an annual rate of 35.0 days lost performance per worker with ADHD. 5 Unlike the previous three studies, Torgersen and colleagues chose a medical chart review in lieu of a survey study design to assess the impairments associated with adult ADHD. 6 Based on the 45 charts of adults diagnosed with ADHD reviewed, only 15.6% (n=7) of participants were employed and 68.8% (n=31) were receiving some social assistance benefit. While these studies do highlight an association between adult ADHD and unemployment and work performance, there are a few limitations of note. First, the use of self-reporting methods for the diagnosis of adult ADHD could lead to an under-estimation of prevalence. Second, the criteria for definitively diagnosing ADHD in adults were developed based on criteria for children and may not be generalizable or less applicable to adults. Finally, at least two of the above mentioned studies make use of multiple imputation methods to estimate ADHD, potentially reducing the precision and generalizability of results. Overall, the evidence linking adult ADHD to increased unemployment and poorer work performance is weak and should be interpreted with caution.
As with unemployment, there have been studies to estimate impact of adult ADHD on criminality. In addition to studying unemployment, Torgersen and colleagues looked at criminality. In addition to the National Patient register to determine diagnosis, authors used both the Prescribed Drug Register and National Crime Register to examine the association between the use of ADHD medication and criminality. Among men with ADHD (n=16,087), 53.6% had taken an ADHD medication and 36.6% had been convicted of a crime during follow-up. Compared to men, a greater proportion of women with ADHD (n=9569) had taken ADHD medication (62.7%), and fewer had been convicted of a crime (15.4%). For both men and women, results from the analysis suggest that crimes occurred less frequently (32% reduction for men; 41% reduction for women) when patients were receiving medication for their ADHD. Authors also tested for any long-term associations by looking at medication use in 2006 and criminality in 2009, but found no significant associations between receipt of medication and criminality. While the results from this study support the claim that receiving ADHD medication reduces the rate of criminality among adult patients with ADHD, there were some limitations that must be considered. First, there is a risk of bias due to reverse causation (i.e., are patients who are more likely to take treatment, less likely to commit crimes?). Authors attempted to control for this by analyzing data to determine if order of medication status was important and found that the associations remained significant regardless of the order of medication status. The second limitation is the limited follow-up period, which did not allow for extensive analysis of whether associations persist after medication is discontinued. A third limitation is the risk that unmeasured confounders (i.e., confounding by indication) might be influencing the results. Finally, given that this study was conducted using a Swedish population, its applicability to the Canadian context is questionable.
A second Swedish study used an existing cohort of adult males with ADHD undergoing treatment for severe substance abuse disorder to examine the association between receiving ADHD medication and long-term functional outcomes, including employment status. Half of the participants (n=30) were treated with ADHD medication and the other half were not. At the time of follow-up, only 24 patients (15 in the treated group and 9 in the untreated group) were considered for employment status, as the remaining participants were either institutionalized or on sick-leave. Among those considered in the treated group 6/15 were employed, while 4/9 were employed in the untreated group, and this difference was considered statistically significant (p=0.028). Overall, this study does provide limited evidence of a positive association between receiving ADHD medication and employment; however, there are several limitations. Given the pragmatic nature of this study design, it is possible that confounding by indication may have influenced the results, though researchers attempted Nov 23, 2015 odprn.ca
Ontario Drug Policy Research Network to control for as many extraneous factors as possible in their analysis. There are also limitations with respect to applicability and generalizability of the study results. In addition to ADHD, patients enrolled in this study had comorbid substance abuse problems and/or antisocial behaviour, both of which are not seen amongst all adult ADHD patients, but do affect a substantial portion. Additional considerations include: differing duration of follow-up between treated and untreated groups, relatively high amounts of missing data in the untreated group, and limited data regarding the treatment regimen or adherence to medication. For these reasons, caution should be taken in interpreting these results with respect to the Canadian context.
A third study conducted in the United States assessed the functional impairment (including work performance) of adults with ADHD after six months of double-blind treatment with either atomoxetine or placebo. 9 The study population consisted of 410 employed, adult ADHD patients aged 18 to 50 years old from 22 outpatient treatment centres across the United States. Of the 410 participants, 271 received atomoxetine (non-stimulant medication) while the remaining participants received placebo (n=139). The primary functional outcome measure for this study was the Endicott Work Productivity Scale (EWPS), a self-report questionnaire that assesses attendance, lost hours and presenteeism at work. After one month of treatment, the treated group exhibited greater improvement in work performance according to their EWPS score than patients in the untreated group (p<0.01). After six months of treatment there were no significant differences between groups. The mean reduction in EWPS score for the treated group was 16.2 (SD=18.4) points and 15.6 (SD=16.0) points for the untreated group. These results suggest that, if any, the association between receiving atomoxetine and improved work performance is marginal. Despite the randomized nature of this study there are some limitations to note. First, there was an extremely high attrition rate; only 104/271 (38.4%) and 68/139 (48.9%) of participants in the treated and untreated groups, respectively, completed the study. Generalizability of the study results is noted as patients with other psychiatric illnesses were excluded. Patients with ADHD are vulnerable to other comorbidities such as substance abuse, anxiety and affective disorders; thus, without including these patients in the present study, results may not be applicable to the adult ADHD population as a whole. A third limitation is that several of the authors have affiliations with industry (Eli Lilly, manufacturer of atomoxetine). For these reasons, caution should be taken in the interpretation of these results and their applicability to the Canadian context.
In conclusion, some literature supporting the claim that adult ADHD has a negative impact on some societal factors, such as work performance and criminality, was identified. Additionally, we found some evidence suggesting that receiving ADHD medication improves work performance and reduced the likelihood of criminal behaviour. As mentioned above, there are several limitations to this evidence base including, small numbers of participants and poor generalizability. There was also little mention of the economic implications of adult ADHD from a broader societal perspective. Based on these findings, we conclude that more research is needed in this area, particularly in the Canadian context, so that we can better understand the economic impact of ADHD and ADHD medications.
Overall Conclusions
Based on the findings from both our systematic review and our post-hoc literature review, we have determined that little is known about the economic impact of adult ADHD. There is a 
Appendix A2: Results of Search
The following illustrates the selected studies for the review.
• All of the models considered the following variables: quarter (i.e., January 1-March 31, 2000 was quarter 1, April 1-June 30, 2000 was quarter 3, etc.), and the number of available ADHD medications covered by OPDP. We also had to adjust our predictive models where necessary for short-acting stimulants based on the addition of lisdexamfetamine in 2011 to OPDP coverage, as this substantially impacted the use of short-acting stimulants. Each model was examined for seasonal effects based on absolute and Winters' seasonal effects calculations. For each model, the most suitable combination of independent variables and inclusion of seasonal effects were selected based on the Bayesian information criterion (BIC). We developed prediction models for each age category provided to us by OPDP (<18 years, 18-25 years, 26-35 years, 36-64 years, 65+ years, and all ages). Based on our preliminary results from these models, we decided to collapse all adults into a single group (≥18 years) for comparison with the under 18 group. The final models were chosen based on best fit parameters calculated as part of our model building (see Appendix B1: Model Details for more details). For long-acting stimulants, the power model with no seasonal effects was chosen for the under 18 age group, and the constant growth model with no seasonal effects was chosen for the 18 and over age group. For short acting stimulants, a power model with seasonal effects was chosen for the under 18 age group and an exponential model with seasonal effects was chosen for the 18 and over age group. Finally, for non-stimulant, a power model with no seasonal effects was chosen for the under 18 age group and a linear model with seasonal effects was chosen for the over 18 age group.
Once forecasts for the number of users were obtained for 2015-2017, number of users was then converted to expenditure by multiplying the total number of users per year by average units per user per quarter in the last year and average cost per unit in the last year (Status Quo). Expenditures under alternative reimbursement strategies were estimated. The alternative strategies considered are outlined below Table 1 . Table 1 . Alternative reimbursement strategies for ADHD medications covered by OPDP.
Strategy Assumptions 1a.
Status quo: no changes. General benefit (GB): short-and longacting stimulants Exceptional access program (EAP): atomoxetine.
Use current utilization trends to forecast costs for 2015-2017.
1b.
Same as 1a EXCEPT: limited use (LU) -atomoxetine.
Assume 10% of ADHD patients currently on short-or long-acting stimulants will move to atomoxetine. Also assume the price for atomoxetine is reduced to 25% of the brand price. GB -short-acting stimulants GB -long-acting stimulants (<18 years) LU/step therapy -long-acting stimulants (18+ years) EAP -atomoxetine Assume 10% of those currently on longacting stimulants will move to short-acting stimulants.
2b.
Same as 2a EXCEPT LU -atomoxetine Assume 10% of short-acting and longacting stimulant users move to atomoxetine. Also assume the price for atomoxetine is reduced to 25% of the brand price. Assume 10% of those remaining on long-acting stimulants will move to short-acting stimulants.
3a.
Same as 2a EXCEPT GB -extended release methylphenidate (18+ years) LU/step therapy -brand name only longacting (failed/intolerant generic product)
Assume 10% of users currently on longacting stimulants move to methylphenidate and assume 10% of remaining move to short-acting stimulants.
3b.
Same as 3a EXCEPT LU -atomoxetine Assume 10% of users on short-and longacting stimulants move to atomoxetine. Also assume the price for atomoxetine is reduced to 25% of the brand price.Of remaining long-acting stimulant users, 10% move to methylphenidate. Finally, 10% of the remaining users move to shortacting stimulants.
4
Same as 2a EXCEPT GB -long-acting stimulants (<25 years) LU/step therapy -long-acting stimulants (25+ years)
Assume 10% of long-acting stimulant users, 25 years and older, move to shortacting stimulants.
Findings Current Usage and Expenditure
For adult ADHD patients (≥18 years), the total average number of users, units, and prescriptions per quarter for ADHD medications in 2014 was 17,482, 2,677,072, and 93,472, respectively. For ADHD patients under age 18, the total average number of users, units, and prescriptions per quarter for ADHD medications in 2014 was 13,529, 1,294,217, and 36,533, respectively. Among children and adults alike, long-acting stimulants account for the majority of ADHD medication usage (54-89%) with extended release methylphenidate being the most popular of the long-acting stimulants. See Table 2 for further information about current usage. OPDP expenditure for ADHD medication among both children and adults has increased significantly since 2000. Among adults spending has risen from $736,000 in 2000 to over $14.5 million in 2014 (Table 3) . A similar trend is seen among children with expenditure increasing from $1.5 million to over $10.6 million over the last 15 years (Table 4 ). In 2014, long-acting stimulants accounted for, by far, the majority of OPDP expenditure for ADHD medications among both children and adults. Based on expenditure in 2014, long-acting methylphenidate held the largest market share for patients under age 18 ( Figure 1 ) and patients aged 18 years and older ( Figure 2 ) with 46% and 34%, respectively. Long-acting dextroamphetamine had the smallest market share (<1%) for patients under 18 years old, while atomoxetine had the smallest share (2%) for patients age 18 and older. 
Forecasting expenditure
For both children and adults, overall expenditure for ADHD medications is expected to continue to grow over the next three years ( Figure 3 , Figure 4) , with long-acting methylphenidate accounting for the greatest growth. No major increases in expenditure are expected in either age group for short-acting stimulants or non-stimulants over the next three years ( Figure 3, Figure 4 ).
AMS 22% DEX -LAS 4%
MET -LAS 36% Without any changes to current reimbursement for ADHD medications, expenditure is expected to rise to $12.1 million in 2017 for children (<18 years old) and $23.2 million for adults (≥18 years old) ( Table 5, Table 6 ).
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EXPENDITURE

Impact of Alternative Approaches to Reimbursement
Because this review is focused on adult ADHD patients, some of the alternative reimbursement strategies do not impact ADHD medication expenditure for children (<18 years); however, if a LU listing for atomoxetine were to be implemented for all age groups, expenditure would decrease by 6% in some cases (strategies 1b, 2b, 3b) among children by 2017 (Table 7) .
For adults over 18 years with ADHD, all of the alternative reimbursement strategies resulted in a reduction in overall expenditure for ADHD medications (Table 8) . Listing atomoxetine as limited use in addition to a general benefit listing for extended release methylphenidate and a limited use listing for brand name only long-acting stimulants with enforced step therapy (strategy 3b) offers the largest reduction in expenditure (-13%) by the end of 2017. Moreover, strategy 2b (LU listing for atomoxetine and long-acting stimulants with enforced step therapy) and strategy 3a (GB for extended release methylphenidate & LU listing/step therapy for brand name only long-acting stimulants) each lead to an 8% decrease in overall ADHD medication expenditure. The remaining strategies result in reductions in expenditure of 3-5%. 
Overall Conclusions
In conclusion, without any changes to current reimbursement for ADHD medications, expenditure is expected to increase to $12.1 million for children (<18 years) and $23.2 million for adults (≥18 years). Listing atomoxetine as limited use in addition to a general benefit listing for extended release methylphenidate and a limited use listing for brand name only longacting stimulants with enforced step therapy (strategy 3b) would generate the greatest reduction (-13%) in overall expenditure for adult ADHD medications by the end of 2017. Strategy 2b (LU listing for atomoxetine and long-acting stimulants with enforced step therapy) 
